Cullinan Announces Q2 Financials and Clinical Pipeline Updates
Cullinan Therapeutics released Q2 results and shared clinical data, including plans to begin a potentially registrational Phase 2 study for CLN-049 and confirm Phase 2 expansions for CLN-978 and velinotamig by early 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day